Telix Pharmaceuticals (ASX:TLX) - Prezzo delle azioni, notizie e analisi

TLX Panoramica delle azioni

TLX analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	6/6
Prestazioni passate	3/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 48% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 38.32% all'anno

È diventato redditizio quest'anno

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Telix Pharmaceuticals Limited Concorrenti

Race Oncology

ASX:RAC

AU$237.8m

Clinuvel Pharmaceuticals

ASX:CUV

AU$680.3m

CSL

ASX:CSL

AU$131.4b

Orthocell

ASX:OCC

AU$151.8m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Telix Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$22.96
Massimo di 52 settimane	AU$23.99
Minimo di 52 settimane	AU$9.06
Beta	2.38
1Variazione di 1 mese	6.84%
Variazione a 3 mesi	16.08%
Variazione di 1 anno	151.20%
3Variazione a 3 anni	214.95%
Variazione a 5 anni	1,219.54%
Variazione dall'IPO	2,881.82%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	TLX	AU Biotechs	AU Mercato
7D	-0.09%	-5.0%	1.4%
1Y	151.2%	9.8%	17.7%

Ritorno vs Industria: TLX ha superato il Australian Biotechs che ha restituito 9.8 % nell'ultimo anno.

Rendimento vs Mercato: TLX ha superato il mercato Australian che ha restituito 17.7 % nell'ultimo anno.

Volatilità dei prezzi

Is TLX's price volatile compared to industry and market?
TLX volatility
TLX Average Weekly Movement	5.8%
Biotechs Industry Average Movement	10.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: TLX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di TLX è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	423	Chris Behrenbruch	telixpharma.com

Telix Pharmaceuticals Limited, una società biofarmaceutica in fase commerciale, si concentra sullo sviluppo e la commercializzazione di radiofarmaci terapeutici e diagnostici per il cancro e le malattie rare in Australia, Belgio, Giappone, Svizzera e Stati Uniti. L'azienda offre Illuccix per il trattamento del cancro alla prostata e TLX66-CDx per il trattamento dell'osteomielite per immagini. I suoi prodotti candidati includono TLX591, un coniugato anticorpo-farmaco per il trattamento del cancro alla prostata; TLX250-CDx per il trattamento e la diagnosi del cancro renale; TLX101-CDx per il cancro al cervello (glioma); TLX66-CDx per il trattamento del condizionamento del midollo osseo; TLX300-CDx per il trattamento e la diagnosi del sarcoma dei tessuti molli; e TLX250 per il trattamento del carcinoma renale a cellule chiare.

Telix Pharmaceuticals Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Telix Pharmaceuticals con la sua capitalizzazione di mercato?
TLX statistiche fondamentali
Capitalizzazione di mercato	AU$7.70b
Guadagni(TTM)	AU$49.19m
Ricavi(TTM)	AU$645.68m

156.2x

Rapporto P/E

11.9x

Rapporto P/S

TLX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
TLX Conto economico (TTM)
Ricavi	AU$645.68m
Costo del fatturato	AU$240.33m
Profitto lordo	AU$405.35m
Altre spese	AU$356.16m
Guadagni	AU$49.19m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.15
Margine lordo	62.78%
Margine di profitto netto	7.62%
Rapporto debito/patrimonio netto	2.9%

Come si è comportato TLX nel lungo periodo?

Vedi performance storica e confronto

TLX Panoramica delle azioni

Premi

Analisi del rischio

Telix Pharmaceuticals Limited Concorrenti

ASX:RAC

AU$237.8m

ASX:CUV

AU$680.3m

ASX:CSL

AU$131.4b

ASX:OCC

AU$151.8m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Recent updates

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Consensus EPS estimates fall by 23%

Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent

Second quarter 2024 earnings: EPS misses analyst expectations

Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

Price target increased by 12% to AU$24.04

Price target increased by 10% to AU$20.87

Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024

Price target increased by 14% to AU$21.49

Consensus EPS estimates increase by 10%

Price target increased by 11% to AU$18.89

Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million.

First quarter 2024 earnings released: EPS: AU$0.056 (vs AU$0.027 loss in 1Q 2023)

Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent

Consensus EPS estimates increase by 10%

Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.

Consensus EPS estimates increase by 30%

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024

Now 20% overvalued after recent price rise

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent

Consensus EPS estimates fall by 19%

Price target increased by 7.5% to AU$14.47

Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million.

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.

Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022)

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Co-Founder exercised options to buy AU$1.7m worth of stock.

Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited Announces Executive Changes

Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer

Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Price target increased by 8.0% to AU$13.37

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million.

Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591

Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies

Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023

New minor risk - Shareholder dilution

Forecast to breakeven in 2023

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.23 loss in 1H 2022)

Forecast to breakeven in 2023

Forecast breakeven date moved forward to 2023

Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023

Forecast to breakeven in 2023

Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023

Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Price target increased by 7.5% to AU$11.82